Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 2/20 | 0.39 |
| ▸ | GABBR1 | Q9UBS5 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SAT1 | P21673 | 1/20 | 0.35 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.34 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63984 | 0.82 | BTN3A1 (0.53) | BTN3A1MVDBLMITPR3ITPR1 | |
| SCHEMBL2606244 | 0.81 | — | — | |
| SCHEMBL11408483 | 0.81 | PLA2G2C (0.41) | BTN3A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL19115076 | 0.81 | BTN3A1 (0.44) | BTN3A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL30834684 | 0.80 | BTN3A1 (0.38) | BTN3A1GABBR2GABBR1PLA2G2CMVD | |
| SCHEMBL10881853 | 0.78 | BTN3A1 (0.50) | BTN3A1MVDBLMITPR3ITPR1 | |
| SCHEMBL18736592 | 0.78 | BTN3A1 (0.37) | BTN3A1GABBR2GABBR1PLA2G2CMVD | |
| SCHEMBL12583935 | 0.77 | — | — | |
| SCHEMBL11952605 | 0.77 | SAT1 (0.42) | BTN3A1MVDSAT1 | |
| SCHEMBL19103663 | 0.76 | PLA2G2C (0.39) | BTN3A1GABBR2GABBR1PLA2G2CMVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-8128942-B2 | Anti-sepsis conjugate vaccine | ENDOBIOLOGICS, INCORPORATED (US) | 2012-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | BTN3A1 100/4885GABBR2 652/4885GABBR1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.